Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.
Animals
Apoptosis
/ drug effects
Breast
/ pathology
Caspase 3
/ metabolism
Cell Line, Tumor
Datasets as Topic
Female
G2 Phase Cell Cycle Checkpoints
/ drug effects
Humans
Intravital Microscopy
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
/ agonists
Membrane Potentials
/ drug effects
Mice
Oxadiazoles
/ pharmacology
Patch-Clamp Techniques
Tetrazoles
/ pharmacology
Thiourea
/ analogs & derivatives
Triple Negative Breast Neoplasms
/ drug therapy
Hyperpolarization
Potassium channels
Triple-negative breast cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
26 Jun 2020
26 Jun 2020
Historique:
received:
23
01
2020
accepted:
15
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Unlike other breast cancer subtypes that may be treated with a variety of hormonal or targeted therapies, there is a need to identify new, effective targets for triple-negative breast cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast cancer cells. The primary objective of the study is to explore whether hyperpolarization induced by opening potassium channels may provide a new strategy for treatment of TNBC. Breast cancer datasets in cBioPortal for cancer genomics was used to search for ion channel gene expression. Immunoblots and immunohistochemistry were used for protein expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to study xenograft in female NSG mice. In large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for a voltage- and calcium-dependent large-conductance potassium channel, called BK channel), overexpressed in triple-negative breast cancer patients. Although overexpressed, 99% of channels are closed in TNBC cells. Opening BK channels hyperpolarized membrane potential, which induced cell cycle arrest in G2 phase and apoptosis via caspase-3 activation. In a TNBC cell induced xenograft model, treatment with a BK channel opener significantly slowed tumor growth without cardiac toxicity. Our results support the idea that hyperpolarization induced by opening BK channel in TNBC cells can become a new strategy for development of a targeted therapy in TNBC.
Sections du résumé
BACKGROUND
BACKGROUND
Unlike other breast cancer subtypes that may be treated with a variety of hormonal or targeted therapies, there is a need to identify new, effective targets for triple-negative breast cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast cancer cells. The primary objective of the study is to explore whether hyperpolarization induced by opening potassium channels may provide a new strategy for treatment of TNBC.
METHODS
METHODS
Breast cancer datasets in cBioPortal for cancer genomics was used to search for ion channel gene expression. Immunoblots and immunohistochemistry were used for protein expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to study xenograft in female NSG mice.
RESULTS
RESULTS
In large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for a voltage- and calcium-dependent large-conductance potassium channel, called BK channel), overexpressed in triple-negative breast cancer patients. Although overexpressed, 99% of channels are closed in TNBC cells. Opening BK channels hyperpolarized membrane potential, which induced cell cycle arrest in G2 phase and apoptosis via caspase-3 activation. In a TNBC cell induced xenograft model, treatment with a BK channel opener significantly slowed tumor growth without cardiac toxicity.
CONCLUSIONS
CONCLUSIONS
Our results support the idea that hyperpolarization induced by opening BK channel in TNBC cells can become a new strategy for development of a targeted therapy in TNBC.
Identifiants
pubmed: 32586284
doi: 10.1186/s12885-020-07071-1
pii: 10.1186/s12885-020-07071-1
pmc: PMC7318490
doi:
Substances chimiques
1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)thiourea
0
3-((5-chloro-2-hydroxyphenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one
0
KCNMA1 protein, human
0
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
0
Oxadiazoles
0
Tetrazoles
0
CASP3 protein, human
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Thiourea
GYV9AM2QAG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595Subventions
Organisme : Foundation for the National Institutes of Health
ID : U54GM104942
Organisme : NCI NIH HHS
ID : R01 CA148671
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121322
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052375
Pays : United States
Références
Breast Dis. 2010;32(1-2):35-48
pubmed: 21778573
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E79-88
pubmed: 24367115
Cell Death Differ. 2015 Jan;22(1):58-73
pubmed: 25236395
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Breast Cancer Res Treat. 2010 Apr;120(2):491-8
pubmed: 20135347
Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130094
pubmed: 24493742
World J Gastroenterol. 2008 Aug 28;14(32):4984-91
pubmed: 18763278
PLoS One. 2012;7(8):e41664
pubmed: 22899999
Mol Syst Biol. 2016 Oct 20;12(10):883
pubmed: 27951527
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Annu Rev Physiol. 2002;64:431-75
pubmed: 11826275
Trends Pharmacol Sci. 2015 Dec;36(12):822-846
pubmed: 26538316
Cold Spring Harb Perspect Biol. 2011 Jun 01;3(6):
pubmed: 20961975
Mol Pharmacol. 2007 Oct;72(4):1033-44
pubmed: 17636045
Trends Mol Med. 2010 Mar;16(3):107-21
pubmed: 20167536
Tumour Biol. 1994;15(2):82-9
pubmed: 8184256
Front Physiol. 2014 Oct 09;5:389
pubmed: 25346695
J Med Chem. 2007 Feb 8;50(3):528-42
pubmed: 17266205
Science. 1979 Nov 9;206(4419):700-2
pubmed: 386513
PLoS One. 2012;7(5):e37451
pubmed: 22655048
Front Oncol. 2019 Sep 24;9:933
pubmed: 31612103
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
J Biol Chem. 1990 Jul 5;265(19):11083-90
pubmed: 1694175
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Front Pharmacol. 2020 Feb 28;11:152
pubmed: 32210800
J Biol Chem. 1995 Sep 22;270(38):22434-9
pubmed: 7673230
J Cell Physiol. 2010 May;223(2):359-68
pubmed: 20112292
Front Physiol. 2018 Nov 21;9:1661
pubmed: 30519193
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
J Cell Biol. 2014 Jul 21;206(2):151-62
pubmed: 25049269
Cancer Cell Int. 2016 Mar 31;16:24
pubmed: 27034617
Eur J Neurosci. 2006 Jul;24(2):442-54
pubmed: 16903852
Channels (Austin). 2013 Nov-Dec;7(6):442-58
pubmed: 24025517
J Biomol Screen. 2015 Oct;20(9):1055-73
pubmed: 26303307
Front Physiol. 2015 Feb 06;6:29
pubmed: 25705194
Circ Res. 1994 Aug;75(2):252-60
pubmed: 8033339
Circulation. 2018 Mar 13;137(11):1176-1191
pubmed: 29530893
Nat Rev Mol Cell Biol. 2003 Jul;4(7):552-65
pubmed: 12838338
Cancer Lett. 2008 Aug 18;267(1):116-24
pubmed: 18455293
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Cancer Cell Int. 2016 Sep 22;16:72
pubmed: 27688735
Expert Opin Investig Drugs. 2017 Nov;26(11):1199-1206
pubmed: 28952409
BMC Cancer. 2009 Jul 29;9:258
pubmed: 19640305
J Cardiovasc Pharmacol. 2014 Jun;63(6):533-43
pubmed: 24566462
J Physiol. 1999 Aug 1;518 ( Pt 3):639-51
pubmed: 10420003
Cell Cycle. 2009 Nov 1;8(21):3527-36
pubmed: 19823012
Mutat Res. 2011 Jul-Oct;728(1-2):23-34
pubmed: 21605699
Histochem Cell Biol. 2006 Jun;125(6):725-41
pubmed: 16362320
Cell. 2015 Oct 8;163(2):506-19
pubmed: 26451490
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
BMC Cancer. 2017 Mar 4;17(1):169
pubmed: 28259153
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9487-92
pubmed: 10900263